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Animal models are important tools in the development of new drug candidates against the inﬂammatory bowel diseases (IBDs)
Crohn’s disease and ulcerative colitis. In order to increase the translational value of these models, it is important to increase
knowledge relating to standard drugs. Using the SCID adoptive transfer colitis model, we have evaluated the eﬀect of currently
used IBD drugs and IBD drug candidates, that is, anti-TNF-α, TNFR-Fc, anti-IL-12p40, anti-IL-6, CTLA4-Ig, anti-α4β7 integrin,
enroﬂoxacin/metronidazole, and cyclosporine. We found that anti-TNF-α, antibiotics, anti-IL-12p40, anti-α4β7 integrin, CTLA4-
Ig, and anti-IL-6 eﬀectively prevented onset of colitis, whereas TNFR-Fc and cyclosporine did not. In intervention studies,
antibiotics, anti-IL-12p40, and CTLA4-Ig induced remission, whereas the other compounds did not. The data suggest that the
adoptive transfer model and the inﬂammatory bowel diseases have some main inﬂammatory pathways in common. The ﬁnding
that some well-established IBD therapeutics do not have any eﬀect in the model highlights important diﬀerences between the
experimental model and the human disease.
1.Introduction
The two inﬂammatory bowel diseases (IBDs) ulcerative co-
litis (UC) and Crohn’s disease (CD) aﬀect more than 3.6
million people in the Western world, resulting in a marked
decrease in the patients’ quality of life [1, 2]. The aetiology
is poorly understood, but it has become clear that genetic,
microbial, and environmental factors all play a role [3]. A
massive eﬀort is taking place to develop new and better
therapeutics, and the development of tumor necrosis factor-
α (TNF-α) antagonists has ameliorated the disease in a large
proportionofespeciallyCDpatients[4].However,aboutone
third of the CD patients do not respond to anti-TNF-α treat-
ment and among the primary responders, about one third
loose response or become intolerant to the treatment [5],
thus leaving many IBD patients with inadequate therapeutic
options.
New IBD drugs and drug candidates include anti-
interleukin (IL)-12/-23 (e.g., ustekinumab, briakinumab),
cytotoxic T-lymphocyte antigen 4 immunoglobulin
(CTLA4-Ig, abatacept), anti-IL-6R (tocilizumab), anti-
interferon γ ((IFN-γ), fontolizumab), anti-α4β7( v e d o l -
izumab), anti-α4 integrin (natalizumab), anti-IL-2-Rα
(daclizumab, basiliximab), antigranulocyte macrophage
colony-stimulating factor (anti-GM-CSF, sagramostim),
anti-intercellular adhesion molecule 1 (anti-ICAM-1,
alicaforsen), rIL-18 binding protein (tadekinig-α), IP-
10/CXCL10 (MDX-1100), anti-CD3 (visilizumab), and
anti-CD40L (TNX 100) [6, 7]. These compounds aim at
targeting speciﬁc immunological mechanisms like cellular
adhesion (anti-α4β7, anti-ICAM-1) and costimulation
(CTLA4-Ig, anti-CD40L), key cytokines (anti-IL-12/-23,
anti-IL-6R, anti-IFN-γ) or cells (anti-IL-2Rα/CD25, anti-
CD3), or have speciﬁc immuno-stimulatory (GM-CSF) or
-inhibitory (rIL-10) eﬀects.2 International Journal of Inﬂammation
Animal models are essential for dissecting the role of
the pathological mechanisms in IBD as well as for assessing
the therapeutic eﬀect of intervening with these pathways
[8]. To what extent the data from animal models can be
translated into the clinic diﬀers among the various models
depending, for example, on the model’s etiopathogenesis
and main drivers of disease. There is no single model
which adequately mimics either UC or CD, and to be able
to translate ﬁndings from a model to the human disease,
it is important to know the model’s central pathological
mechanisms and immunological pathways.
Adoptive transferof a subset of CD4+ T cells to syngeneic
SCID or Rag-knock-out mice, results in the development
of a chronic, progressive colitis and wasting disease as ﬁrst
described by Morrissey et al. and Powrie et al. [9, 10].
The colitis symptoms share several features with both CD
and UC (e.g., chronic, progressive disease with diarrhoea
and weight loss, heavily inﬂamed colon—occasionally trans-
mural damage, loss of mucus from goblet cells, Th1/Th17
dominated cytokine proﬁle as found in CD (IFN-γ,T N F - α,
andIL-23).Themodelhasbeenextensivelyusedforstudying
the immunologic background for the disease as well as
testingnewIBDdrugcandidates[11–14].Wehavepreviously
described in detail the development of colitis following
adoptive transfer of CD4+CD25− T cells [15]. Brieﬂy, in
our hands, the adoptively transferred cells expand rapidly
and the mice begin to develop colitis within the ﬁrst two
weeks. At week three, the disease is normally fully developed
with weight loss, loose stools, increased white blood cell
(WBC) count, and a both thickened and shortened colon.
The disease progresses rapidly and by week 5 most mice
have developed severe colitis requiring a termination of the
study. This synchronized and predictable development of
colitis makes it possible to conduct both prevention and in-
tervention studies.
The aim of this study was to analyze the model with
respect to its usefulness in eﬃcacy studies of new IBD drug
candidates by evaluating the eﬀect of known and potential
IBD therapeutics in the model. We have decided to study a
number of compounds, which each has a speciﬁc inhibitory
eﬀect on a central proinﬂammatory pathway. In addition, we
have included some established IBD therapies, suggested to
ameliorate IBD by a broad spectrum of mechanisms.
2.MaterialsandMethods
2.1. Materials. Human CTLA4-Ig (abatacept, Orencia, Bris-
tol-Myers Squibb), human tumor necrosis factor receptor
Fc (TNFR-Fc) (etanercept, Enbrel, Wyeth), enroﬂoxacin
(Baytril, Bayer, equivalent to ciproﬂoxacin), metronidazole
(Flagyl, Sanoﬁ-Aventis), cyclosporine (Sandimmun, Novar-
tis). All surrogate antibodies, that is, anti-TNF-α (clone
XT3.11, rat IgG1), anti-IL-12p40 (clone C17.8, rat IgG2a),
anti-IL-6 (MP5-20F3, rat IgG1), anti-α4β7 (clone DATK32,
ratIgG2a),andisotypecontrols(cIg)(ratIgG2aclone2A,rat
IgG1 clone HRPN and human IgG1-Fc) were from BioXCell,
West Lebanon, New Hampshire, USA.
Dynabeads, Mouse CD4 (L3T4), and DETACHaBEAD
Mouse were from Dynal, Oslo, Norway, and CD25
MicroBead kit from Miltenyi Biotech, Bergisch Gladbach,
Germany.TheantibodiesusedforFACSanalysiswerePerCP-
conjugated anti-CD4 (L3T4) from BD Pharmingen and
FITC-conjugated anti-CD45.2 (104) from eBiosciences, CA,
USA.
2.2. Mice. C.B-Igh-1b/IcrTac-Prkdcscid (C.B-17 SCID) and
BALB/cAnNTac female mice (8–10 weeks) bred under SPF
conditions (M&B Taconic, Denmark) were housed at Novo
Nordisk A/S. Pathology screening was conducted according
to FELASA guidelines. The animal studies were approved by
the Danish Animal Experimentation Inspectorate.
2.3. Induction of Colitis. For induction of colitis, CD4+
CD25− T cells were adoptively transferred from MHC-
compatible Balb/c mice to C.B-17 SCID recipients as
described previously in [15]. In brief, Balb/c splenocytes
were positively selected for CD4+ T cells using Dynabeads
and DETACHaBEAD and depleted of CD4+CD25+ cells
using the CD25 MicroBead kit. The purity of the cells was
always analyzed by ﬂow cytometry before reconstitution
(>98% of the CD4+ cells were CD25−). The recipients were
reconstituted with 300,000 cells by i.p. injection. Peripheral
bloodfromallmicewassubjectedtoﬂowcytometricanalysis
2 or 3 weeks after transfer, and only mice with CD4+ Tc e l l s
(indicating successful transplantation of cells) were included
in the study.
2.4. Experimental Setup. T h ed r u g st e s t e d ,a sw e l la st h e
doses and dosing regimens are described in Table 1.F o r
prevention studies, the mice were treated from the day they
were adoptively transferred with CD4+CD25− T cells and
until sacriﬁce when the disease was fully developed (three
or four weeks after transfer, Figure 1). For the intervention
studies, the treatment was initiated at week three after
adoptive transfer, when the CD4+ T cells had expanded and
caused colitis in the recipients. The treatment was continued
for two weeks until sacriﬁce at week ﬁve. The control groups
for the biologics (except for TNFR-Fc) were treated with the
relevant control immunoglobulin (cIg), that is, rat IgG1 for
anti-TNF-α and anti-IL-6, rat IgG2a for anti-IL-12p40 and
anti-α4β7, and human IgG1-Fc for CTLA4-Ig. The vehicle
groups for cyclosporine and antibiotics received sterile H2O
(Table 1). In the study with antibiotics, we also included a
group, which was not reconstituted but received treatment,
since we suspected that disturbance of the gut microﬂora
in itself could have a marked eﬀect on the measured
disease parameters. We used the same doses and dosing
frequencies for the various compounds in the prevention
andinterventionstudies(Table 1).Theselectionofdosesand
dosing frequencies were based on either literature describing
eﬃcacious treatment in various colitis models or based on
our experience with eﬃcacious treatment in the collagen
induced arthritis model [16–23].
2.5. Monitoring of Disease. Body weight was determined
three times weekly, and mice were sacriﬁced if they lost more
than 20% of their initial body weight. Fecal consistency wasInternational Journal of Inﬂammation 3
Table 1: Study design—administration of compounds.
Compound Dose (mg/kg) cIg/Vehicle Mice per group1 Dose/wk Route
Rat anti-mouse TNF-α 25 rat IgG1 15P/10I,2 2i . p .
Human TNFR-Fc (IgG1) 5–50 NaCl 10P+I 3i . p .
Rat anti-mouse IL-12p40 25 rat IgG2a 10P+I 3i . p .
Rat anti-mouse-IL-6 25 rat IgG1 10p+I 3i . p .
Human CTLA4-Ig (IgG1) 10 hIgG1-Fc3 10P+I 3i . p .
Rat anti-mouse-α4β7 25 rat IgG2a 10P+I 3i . p .
Enro/metro4 350/875 H2O9 P/10I daily p.o.
Cyclosporine 25 H2O1 0 p daily p.o.
1Five to ten unreconstituted mice were included in addition to the compound and the control group.
2P: prevention, I: intervention.
3human IgG1-Fc.
4Treatment with enroﬂoxacin and metronidazole in the drinking water was initiated one week prior to transfer to let the mice adjust to the taste. Although we
in pilot studies had identiﬁed a useful sugar mixture to mask the taste of metronidazole, the mice refused to drink and lost weight prior to adoptive transfer
in the prevention study. Metronidazole was subsequently given orally by gavage once daily (this method was then also used for the intervention study).
evaluatedbeforethestartoftreatmentandatthetermination
of the study using a semiquantitative score (normal stool =
0; slightly soft = 1; soft but formed = 2; not formed = 3;
liquidstoolsornofecesincolonatsacriﬁce=4)aspreviously
described [15] .T h en u m b e ro fW B Cp e rl i t e rw a sa n a l y z e d
in samples (20μL) of EDTA-stabilized peripheral whole
blood, using a Medonic CA 620 (Boule Nordic, Denmark)
blood analysis apparatus according to the manufacturer’s
instructions.
2.6. Postmortem Analysis. Prior to sacriﬁce, the mice were
anesthetized and blood from the periorbital venous plexus
was collected in EDTA-containing tubes. After sacriﬁce, the
colon was excised, rinsed gently with saline, and the weight
and length recorded. The colonic weight-to-length ratio
(W:L) was previously shown to correlate strongly with the
clinical and histological severity of disease [15]. The colon
was opened longitudinally, mounted on a plastic plate, and
ﬁxed overnight in 4% paraformaldehyde.
2.7. Histology. Longitudinal segments of tissue representing
essentially the entire length of the transverse and distal colon
(where the inﬂammation is mainly located) were embedded
in paraﬃn. A section (7μm) of the transverse and the distal
colon from each animal was stained with hematoxylin and
eosin/periodic acid Schiﬀ (H&E/PAS) and analyzed by light
microscopy. A total histological score was calculated for each
animal as described previously [24] and shown in Figure 2.
Brieﬂy, the samples were assigned a score (0–3 or 0–4)
according to the severity (none, mild, moderate, severe)
and extent (none, mucosal, submucosal, transmural) of
inﬂammation, degree of crypt damage (basal 1/3 damaged,
basal 2/3 damaged, crypts lost—epithelium intact, crypts
lost—epithelium lost), and percentage of tissue aﬀected (0,
1–25%, 26–50%, 51–75%, 76–100%).
The histological analyses were performed in a blinded
fashion with respect to the treatment groups.
Healthy Mild colitis
Week after transfer
Severe colitis
Intervention
Prevention
012345
Figure 1: The adoptive transfer colitis model and treatment design.
Forpreventionstudies,themiceweretreatedfromthedaytheywere
a d o p t i v e l yt r a n s f e r r e dw i t hC D 4 +CD25− T cells and until sacriﬁced
when the disease is fully developed (three or four weeks after
transfer). For the intervention studies, the treatment was initiated
at week three after adoptive transfer. The treatment was continued
for two weeks until sacriﬁced at week ﬁve.
2.8. Statistical Analysis. Fecal consistency score and histo-
logical score are shown as median (range) and analyzed
using the Mann-Whitney U-test. WBC count, body weight
at postmortem, and colonic weight:length ratio are shown
as mean ± standard error of the mean (SEM) and analyzed
by Student’s t-test using Welch’s correction for unequal
variances.Diﬀerenceswereconsideredstatisticallysigniﬁcant
when P<0.05.
3. Results
In the following, the disease modifying eﬀect of each of
the investigated compounds in the adoptive transfer colitis
model is presented. A schematic representation of the drug
targets is shown in Figure 3. First, experimental data with
the biologicals (i.e., monoclonal antibodies (mAb) and
receptor fusion proteins (R-Fc)) are presented, followed
by data from a number of compounds currently used to
treat CD or UC. Although broad-spectrum antibiotics and
metronidazolearemainlyusedforsubgroupsofIBDpatients
or for complications like pouchitis, we have included this
treatment regimen, since the inﬂuence of the microﬂora4 International Journal of Inﬂammation
(a) (b)
(c) (d)
(e) (f)
Figure 2: Histological changes in colon after adoptive transfer. Representative photomicrographs of histological changes leading to a
progressively higher score from (a) to (f): (a) normal, (b) mild inﬂammation restricted to the mucosa, (c) moderate mucosal inﬂammation,
(d) severe inﬂammation extending to submucosa, moderate to severe crypt degeneration, (e) severe transmural inﬂammation, moderate to
severe crypt degeneration, (f) as (e) but with ulceration. Original magniﬁcation ×25 for (a-b) and ×10 for (c–f).
in the pathogenesis of IBD is a central topic. Due to the
large data material, readers are referred to the supplementary
material for a complete presentation of data (Figure SF1 and
Tables ST1–ST10 available at doi: 10.1155/2012/412178).
3.1. Rat Anti-Mouse TNF-α mAb Treatment. In the 28 day
preventionstudy,micetreatedwiththeisotypecontrolbegan
tolooseweightaftertwoweeks,whiletheweightcurveforthe
rat anti-mouse TNF-α mAb-treated mice was comparable
to that of healthy controls. At the end of the study, the
anti-TNF-α-treated group had lost signiﬁcantly less weight
than the control group (P<0.001, Figure 4, Tables 2 and
ST1). Two mice in the control group were sacriﬁced due
to extensive weight loss before the end of the study. TheInternational Journal of Inﬂammation 5
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Figure 3: Inhibition of disease pathways in the adoptive transfer model. Schematic representation of drug targets.
Table 2: Statistics for all compounds. Clear lines represent prevention studies and bold represent intervention studies.
Compound Weight change Fecal score WBC count Colonic
weight:length Histological score
Anti-TNFα< 0.001 <0.001 <0.001 <0.001 <0.0001
<0.05 ns ns ns ns
TNFR-Fc† <0.01 ns ns ns —
ns ns ns ns —
Anti-IL-12p40 <0.001 ns <0.05 <0.001 <0.001
<0.0001 ns 0.001 <0.01 <0.05
Anti-IL-6 <0.01 <0.01 ns <0.05 <0.05
ns ns ns ns ns
CTLA4-Ig <0.01 <0.01 <0.01 <0.001 <0.05∗
<0.01 <0.01 <0.001 <0.001 <0.001
Anti-α4β7 <0.0001 <0.01 ns <0.01 <0.01
ns ns ns ns ns
Enro + Metro ns <0.001 <0.05 <0.001 <0.001
<0.01 <0.001 <0.001 <0.0001 <0.001
Cyclosporine ns ns <0.05∗∗ ns ns
——— — —
†Prevention = 50mg/kg, intervention = 5mg/kg.
∗Used Wilcoxon signed rank test and compared with a hypothetical value of 0.0 since all scores were 0 in the CTLA4-Ig group.
∗∗WBC count higher in treatment group—not analyzed.
fecal score was increased in both groups but was signiﬁcantly
lowerintheanti-TNF-αgroup(P<0.001,Tables2andST2).
The WBC count in the anti-TNF-α group was almost as low
as in the unreconstituted controls, while it was signiﬁcantly
higher in the isotype control group (P = 0.001, Table 2
and ST3). Similarly, the colonic W:L ratio (P<0.001)
and histological score (P<0.0001) were signiﬁcantly lower
in the anti-TNF-α group compared to the isotype controls
(Tables 2, SF1, ST4-5). In contrast to the prevention studies,
intervention therapy with anti-TNF-α did not consistently
ameliorate colitis in this model. Although the anti-TNF-α-
treated group lost less weight than the control group (P<
0.05),noneoftheotherclinicalparametersweresigniﬁcantly
aﬀected by the treatment (Table 2 and ST6–10). Both for the
fecal score, colonic W:L ratio and histological score (SF1),
the group seemed equally divided into responders and non
responders, that is, having high or low scores and values,
respectively,ratherthanbeingequallydistributedaroundthe
mean or median.
3.2. TNF-α Receptor Fc Treatment. We ﬁrst tested the human
T N F R - F cf u s i o np r o t e i ne t a n e r c e p ta tad o s eo f5m g / k gi n
a 21 days prevention study and found no signiﬁcant eﬀect
of the compound on any of the parameters analyzed (data6 International Journal of Inﬂammation
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Figure 4: Changes in key disease parameters following treatment. Key disease parameters (weight loss, WBC counts, and colon W:L ratio)
are depicted for preventive treatment (a–c) and interventive treatment (d–f). Disease parameters are shown as ((post mortem weight−start
weight)/Start weight)∗100, (WBC count of drug/WBC count of control)∗100, (W:L ratio of drug/W:L ratio of control)∗100. (a and
d) White bars represent vehicle control groups, grey bars represent treatment groups, and black bars represent mice which were not
reconstituted but received treatment. (b, c, e, and f) Grey bars represent relative WBC counts and W:L ratios.
not shown). In the subsequent 28 days prevention study with
a dose of 50mg/kg, this group had signiﬁcantly less weight
loss than the vehicle control group (P<0.01), while the
fecal score was slightly but not signiﬁcantly lower (Figure 4,
Tables 2 and ST1-2). One mouse in the vehicle control
g r o u pw a ss a c r i ﬁ c e db e f o r ew e e kf o u r ,d u et oe x t e n s i v e
weight loss. There was no diﬀerence in the mean WBC count
or colonic W:L ratio between the two groups. Since we
found no eﬀects of the compound (except from decreased
weight loss) and since the colonic W:L ratio is highly
predictable for the histological score (as described in [15]),
no histological scoring was made. In the intervention study,International Journal of Inﬂammation 7
TNFR-Fc (5mg/kg) did not aﬀect any of the measured
parameters (Table 2 and ST6–10). Since the prevention study
using 50mg/kg did not have any eﬀect either, this dose was
not tested in intervention studies.
3.3. Rat Anti-Mouse IL-12p40 mAb Treatment. In the 28-day
preventionstudy,micetreatedwiththeisotypecontrolbegan
tolooseweightaftertwoweeks,whiletheweightcurveforthe
rat anti-mouse IL-12p40 mAb-treated mice was comparable
to that of healthy controls. At the termination of the study,
mice treated with anti-IL-12p40 mAb had lost signiﬁcantly
less weight than the isotype control group (P<0.001)
(Table 2 and ST1). Similarly, anti-IL-12p40 mAb treatment
resultedinsigniﬁcantlylowerWBCcount(P<0.05),colonic
W:L ratio and histological score (SF1) (P<0.001 for both
parameters),whileitdidnotsigniﬁcantlyimprovefecalscore
(Tables2andST2-S5).Interventionwithanti-IL-12p40mAb
from day 21 reversed the progressive weight loss. At the end
of the study, this group had lost signiﬁcantly less weight
than the control group (P<0.0001) (Table 2 and ST6).
The fecal score tended to be lower in the anti-IL-12p40 mAb
group, and the colonic W:L ratio and histological score were
signiﬁcantly reduced compared to the isotype control (P<
0.01 and P<0.05, resp., Tables 2, SF1, and ST7-10).
3.4. Rat Anti-Mouse IL-6 mAb Treatment. Preventive treat-
ment with a rat anti-mouse IL-6 mAb reduced weight loss
(P<0.01) and fecal score (P<0.01) but failed to
signiﬁcantly reduce WBC counts compared to the isotype
control group (Table 2 and ST1–3). The colonic W:L ratio
of the anti-IL-6 mAb treated group was signiﬁcantly lower
than that of the isotype treated group and was comparable
to the unreconstituted healthy control group (Table 2 and
ST4). Similarly, the histological score was signiﬁcantly less
in the anti-IL-6 mAb-treated group compared to the isotype
control (P<0.01, Tables 2, SF1, and ST5). Intervention with
anti-IL-6 mAb from day 21 did not signiﬁcantly aﬀect any of
the measured parameters (Tables 2, SF1, and S6-10).
3.5. Human CTLA4-Ig Treatment. Preventive treatment with
human CTLA4-Ig eﬀectively inhibited development of col-
itis. The weight curves for CTLA4-Ig-treated mice were
comparable to the weight curves for the unreconstituted
healthy control mice. The fecal score at the termination of
the study (P<0.01), the WBC count (P<0.01), and
colonic W:L ratio (P<0.001) were signiﬁcantly lower in
the CTLA4-Ig groups compared to the isotype control group
(Table 2 and ST1–4). Remarkably, no signs of inﬂammation
were found in any of the animals, suggesting a very potent
eﬀect of the compound (Tables 2,S F 1 ,a n dS T 5 ) .
Ap r o f o u n de ﬀect of CTLA4-Ig treatment on all the mea-
sured parameters was likewise identiﬁed in the intervention
study. Shortly after initiation of treatment, the weight loss
was reversed and the animals gained weight comparable to
the unreconstituted. Likewise, the fecal score (P<0.01),
WBC count (P<0.001), colonic W:L ratio (P<0.001), and
histological score (P<0.001) were signiﬁcantly lower than
for the isotype control group at the end of the study (Tables
2, SF1, and ST6-10).
3.6. Rat Anti-Mouse α4β7 Integrin mAb Treatment. Preven-
tive treatment with a rat anti-mouse α4β7 mAb diminished
weight loss (P<0.001) and fecal score (P<0.05, Table 2).
However, the number of WBC was not signiﬁcantly changed
(Tables 2 and ST2-3). Inhibition of T-cell homing to the
gut by anti-α4β7 mAb treatment reduced colonic disease as
indicated by the signiﬁcantly lower colonic W:L ratio and
histological score compared to the isotype control group
(P<0.01 for both parameters, Tables 2,S F 1 ,a n dS T 4 -
5). Intervention with anti-α4β7 mAb at day 21 did not
signiﬁcantly aﬀect any of the measured parameters (Figure 4,
Tables 2, SF1, and ST6–10).
3.7. Antibiotic (Enroﬂoxacin and Metronidazole) Treatment.
Mice treated with antibiotics (unreconstituted and reconsti-
tuted) did not develop weight loss in a preventive setting.
In contrast, reconstituted vehicle treated mice progressively
lost weight (Figure 4). The fecal score was slightly increased
by the treatment itself but was signiﬁcantly lower in the
reconstituted mice treated with antibiotics compared to the
reconstituted vehicle group (P<0.001) as was the WBC
count (P<0.05), the colonic W:L ratio (P<0.001), and
the histological score (P<0.001, Tables 2,S F 1 ,a n dS T 2 - 5 ) .
Intervention with antibiotics immediately reversed
weight loss (Figure 4). At the termination of the study, the
micetreatedwithantibioticshadlostsigniﬁcantlylessweight
than the vehicle control group (P<0.01). Likewise, fecal
score (P<0.0001), WBC count (P<0.001), colonic W:L
ratio (P<0.0001), and histological score (P<0.001)
were signiﬁcantly lower than for the vehicle control group
(Figure 4, Tables 2,S F 1 ,a n dS 7 – 1 0 ) .
3.8. Cyclosporine Treatment. Cyclosporine had no eﬀect on
the degree of weight loss, fecal score, colonic W:L ratio
or histological score, while the WBC count at necropsy
was actually signiﬁcantly higher in the cyclosporine group
compared to the vehicle group (Table 2,S F 1 ,a n dS T 1 - 5 ) .
Since there were no eﬀects of cyclosporine in the prevention
study, the compound was not tested in intervention studies.
3.9. Summary of Experimental Data. Collectively, we found
that CTLA4-Ig, anti-IL-12p40 mAb, and antibiotics pre-
vented onset of colitis and cured established disease, while
anti-TNF-α mAb, anti-IL-6 mAb, and anti-α4β7m A bp r e -
vented onset of colitis but did not reverse established disease.
Neither TNFR-Fc nor cyclosporine had any preventive or
therapeutic eﬀect in the current setup.
4. Discussion
The search for improved treatment opportunities against
IBDisheavilydependentupongoodanimalmodels,bothfor
eﬃcacy studies and for understanding the underlying cause
of the disease. To have any predictive value, the models must
share central drivers of disease with the human disease they8 International Journal of Inﬂammation
are representing. Intervention with some of the known main
mechanisms in autoimmune disease (i.e., costimulation, T-
cell homing, eﬀect of cytokines, etc.) can teach us more
about which pathways are central for the model. This allows
one to select a model appropriate for the inﬂammatory
pathway, the test compound is supposed to act on. The aim
of our study was to estimate the preventive and therapeutic
eﬀect of a number of established or potential IBD drugs,
using the SCID adoptive transfer colitis model. By using
multiple drugs inhibiting potential or known pathogenic
drivers in IBD, we sought after an increased understanding
of the central drivers, in this speciﬁc model. Several of these
compounds or their surrogate antibodies have previously
been tested in colitis models, but never in the same
study with essentially similar experimental setup and with
compounds which are all commercially available. This allows
a more precise comparison of the diﬀerent compounds and
thereby a better assessment of the model’s predictive value.
Wechosetheadoptivetransfercolitismodelnotonlybecause
of its similarities with IBD (mainly CD), but also because
themodelhasseveralpracticaladvantagescomparedtoother
chronic colitis models in relation to pharmacological testing
(e.g., the synchronized onset of disease, no generation of
anti-drug antibodies and commercial availability of mice).
TNF-α is a key proinﬂammatory cytokine in IBD. The
cytokine exerts its eﬀects via activation of NFκBa n dM A P K
pathways, and subsequently induction of IL-6 and IL-1b,
inhibition of T-cell apoptosis, chemoattraction, and so forth
[25]. We found a signiﬁcant preventive treatment eﬀect of
anti-TNF-α mAb, as has been previously described in the
CD45RBHigh model [11]. Our model setup suggests that
TNF-α is most important in the beginning of disease since
anti-TNF-α was largely eﬀective in the prevention study. It is
possible that the redundancy of the inﬂammatory cascades
makes TNF-α less important when the inﬂammation is
already established and CD4+ T cells have diﬀerentiated
into a pathogenic eﬀector phenotype. However, the human
anti-TNF-α mAb’s (adalimumab and inﬂiximab) can induce
remission in the majority of CD patients. These mAbs’ have
been reported to neutralize TNF-α as well as to induce
apoptosis in T cells [26]. Whether the surrogate rat anti-
mouse TNF-α mAb also has this dual function is unknown.
As opposed to anti-TNF-α mAb treatment, there was no
eﬀect of TNFR-Fc in our studies, which is in accordance to
the ﬁndings in CD [27].
IL-12p40 is predominantly produced by dendritic cells
and phagocytes in response to microbial stimulation. It has
a critical role in promoting the diﬀerentiation of na¨ ıve CD4+
T cells into mature T-helper eﬀector cells. It is currently
believed that IL-12 (p23/p40) and IL-23 (p19/p40) are
central for the Th1 and the Th17 pathways, respectively,
and both cytokines are inhibited by the anti-IL-12p40 mAb
[16, 28]. We found that the anti-IL-12p40 mAb treatment
was eﬀective in our prevention as well as intervention setup,
suggesting the importance of these pathways in the transfer
model.Ourobservationisinagreementwithpreviousresults
[20, 29, 30]. Signiﬁcant clinical responses following treat-
ment with an anti-IL-12p40 mAb have also been reported in
CD patients [5, 31], and the drug is currently recruiting for a
phase III trial in CD. Thus, our results suggest that the SCID
adoptive transfer model is suitable for studying compounds
targeting the IL-12p40 pathways.
IL-6 is a pleiotropic cytokine with a central role in
immune regulation. Increased serum concentrations of IL-
6 were reported to correlate with clinical activity of CD, and
antibodies targeting IL-6 or IL-6R were eﬃcacious in several
animal models [16, 32, 33]. In accord, a humanized mAb
against IL-6R showed promising results in a phase II study
in active CD [6]. We found a signiﬁcant therapeutic eﬀect of
anti-IL-6 in a preventive setting but not in the intervention
study. As for the anti-TNF-α mAb treatment, this suggests
that IL-6 is most important in the beginning, while the
redundancyoftheinﬂammatorycascadesmaymakeIL-6less
important when the inﬂammation is already established.
CTLA4-Ig binds to CD80/86 thereby preventing cos-
timulation of T cells via CD28 [34]. CTLA4-Ig has shown
therapeutic eﬃcacy in several autoimmune diseases includ-
ing rheumatoid arthritis, and in experimental models of
autoimmune diseases [34, 35]. We found that CTLA4-
Ig completely prevented colitis and very eﬃciently cured
established disease, indicating a central role of T-cell cos-
timulation in the model. However, shortly after completion
of our experimental studies, clinical trials with CTLA4-Ig in
UC and CD were terminated due to lack of eﬃcacy [36].
The lack of negative regulation through CTLA-4 on, for
example, Tregs may yield a therapeutic window which is
not present in humans. Thus, the lack of important self-
regulatory mechanisms must be taken into account when
evaluating drugs targeting this speciﬁc pathway.
Neutralization of the integrin α4β7o nl y m p h o c y t e s
and monocytes inhibits homing of the cells to the gut via
mucosal addressin cell adhesion molecule-1 (MAdCAM-
1) on endothelial cells. We found that this could prevent
the onset of disease in the transfer model as demonstrated
previously [37]. However, once the colitis was already
established, recruitment of leucocytes to the colon via this
mechanism seemed no longer essential for maintenance of
disease in our experimental setup. In contrast, resolution of
established disease has been demonstrated in the cotton-top
tamarin (spontaneous colitis) [38].
InphaseIIstudies,Vedolizumab(targetinghumanα4β7)
failed to meet the primary endpoint in CD patients with
active disease, while there was a signiﬁcant therapeutic eﬀect
in patients with UC [39, 40]. Natalizumab, which neutralizes
α4 in conjunction with β7a sw e l la swi t hβ1, was eﬀective for
CD and is approved by the FDA to use in patients refractory
to treatment with anti-TNF-α [41].
Thus, in IBD as well as in the models, there is not a
clear-cut eﬀectof inhibiting leukocyte homing via anti-α4β7,
although it seems more eﬀective in man than in the SCID
transfer model. This could be due to the slower progression
of the human disease, that is, there is a larger “window open
for treatment” where recruitment of cells to the gut is still
important. An alternative explanation is the involvement of
α4β7 in homing to the small bowel and Payer’s patches in
Crohn’s disease compared to α4β7 involvement in colonic
CD4+ T cell inﬁltration in the SCID adoptive transfer model.International Journal of Inﬂammation 9
Although anti-α4β7 could not reverse established colitis
inthemodel, themarkedeﬀectoftheantibody inprevention
studies suggests that the model is useful in studies of
leukocyte homing to the colon via integrins and adhesion
molecules.
Cyclosporine inhibits calcineurin, thereby inhibiting T-
cell activation and proliferation. The compound is eﬀective
in patients with severe steroid-refractory UC [7, 42], while
no controlled studies have shown eﬀect of cyclosporine
in CD [43]. We did not ﬁnd any eﬀect of preventive
treatment with cyclosporine in accord with previous studies
in transfer models [35, 44]. In contrast, cyclosporine sig-
niﬁcantly ameliorated acute DSS-induced colitis [19, 45].
Considering that the DSS model is mainly UC-like and
the transfer model mainly CD-like (at least in terms of
Th1/TH17 immunopathogenesis), data from experimental
models are translational to the human disease. It is not
clear why cyclosporine lacks eﬀect in CD and in our model,
but it has previously been shown that T cells are able to
proliferate and exert eﬀector functions via cyclosporine-
resistant mechanisms [46–48]. In addition to its eﬀect on T
cells,cyclosporinehasbeenshowntoinhibittheeffectofsev-
eral other immune cells and proinﬂammatory mechanisms,
which may account for its therapeutic eﬀects in the acute
DSS model, where T cells are not required for development
of disease [49].
The normal intestinal microbial ﬂora (microbiota) con-
tributes signiﬁcantly to the etiopathogenesis of IBD [3, 50],
and antibiotics have in some studies been shown to induce
and maintain remission in IBD patients [50]. However, the
side-eﬀects and the risk of developing microbial resistance
associated with long-term treatment with antibiotics prevent
the use of this treatment strategy. Instead, there is focus
on developing microbial cultures, which can help bringing
back the balance between the microbiota and the immune
system [50]. We found that the combination of enroﬂoxacin
and metronidazole completely prevented onset of colitis
and cured established colitis in the adoptive transfer model,
emphasizing the signiﬁcanceof the microbiota inthis model.
Thus, the experimental model and the human disease share
this central factor in the immunopathogenesis, suggesting
that the model may be useful in studies of the microﬂora’s
impact on disease. Combined treatment with metronidazole,
which kills anaerobes and inﬂuences cell traﬃcking [51], was
essential since enroﬂoxacin alone did not aﬀect the disease
(data not shown).
5. Concluding Remarks
We have evaluated the therapeutic eﬀect of a number of IBD
drugs and drug candidates in the SCID adoptive transfer
colitis model and compared this to the therapeutic eﬀect
in IBD patients, when this information was available. The
study shows that certain drivers of inﬂammation are shared
between the model and the human diseases, that is, the
cytokines IL-12p40, TNF-α and IL-6, the homing molecule
α4β7, and the microbial ﬂora. With regards to these drivers,
the model seems to have a good predictive value.
However, our studies indeed also show limitations of the
adoptive transfer model in this respect, since not all drugs
eﬀective against IBD are eﬀective in the model. Following
adoptive transfer, the development of disease is driven by
the extreme expansion of the CD4+ cells in a lymphopenic
host, and neither B cells nor CD8+ cells are present. Thus,
some treatment eﬀects in the preventive studies might be
due to interfering with homeostatic expansion, which is not
relevant in IBD and conversely, a test compound’s eﬀect on B
and CD8+ T cells will have no eﬀect in the model, although
it might be eﬀective in IBD. Moreover, compared to clinical
trials where eﬃcacy is evaluated, for example, 4–18 weeks
post-initiation of treatment for some test compounds, an
intervention period of two weeks may be too short to obtain
a therapeutic eﬀect in the model. This could be addressed
with a model where the disease is progressing more slowly.
This stresses the need of critically choosing for which types
of experiments and compounds to use animal models and
which of the models to use. It should be noted that there is
a great variability in the disease pattern in IBD patients, and
that patients respond diﬀerently to medication. The various
experimental colitis models may represent diﬀerent types
a n ds t a g e so fs e v e r i t yo fU Co rC D[ 13] and altogether this
makes the translation of data from experimental models to
humans even more challenging.
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